2-alkylaminoethyl-1,1-bisphosphonic acids are potent inhibitors of the enzymatic activity of Trypanosoma cruzi squalene synthase

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4483-4486

  Rodrígues Poveda, Carlos A ^a   González Pacanowska, Dolores ^a   Szajnman, Sergio H ^b   Rodríguez, Juan B ^b  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

1,1 BISPHOSPHONIC ACID DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; GERANYLTRANSFERASE; SQUALENE SYNTHASE; SQUALENE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; NONHUMAN; PRIORITY JOURNAL; TRYPANOSOMA CRUZI;

ANTIPARASITIC AGENTS; CHAGAS DISEASE; DIPHOSPHONATES; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; GERANYLTRANSTRANSFERASE; PARASITIC SENSITIVITY TESTS; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 84864386774     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00796-12     Document Type: Article

References (41)

1. Brener Z. 1973. Biology of Trypanosoma cruzi. Annu. Rev. Microbiol. 27:347-382.
2. Cheng F, Oldfield E. 2004. Inhibition of isoprene biosynthesis pathway enzymes by phosphonates, bisphosphonates, and diphosphates. J. Med. Chem. 47:5149 -5158.
3. Ciosek CP, Jr, et al. 1993. Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo. J. Biol. Chem. 268:24832-24837.
4. Coxon FP, Thompson K, Rogers MJ. 2006. Recent advances in understanding the mechanism of action of bisphosphonates. Curr. Opin. Pharmacol. 6:307-312. (Pubitemid 43670914)
5. Docampo R, Moreno SNJ. 2008. The acidocalcisome as a target for chemotherapeutic agents in protozoan parasites. Curr. Pharm. Des. 14:882-888. (Pubitemid 351736420)
6. Dunford JE, et al. 2001. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296:235-242. (Pubitemid 32112446)
7. Ferella M, et al. 2006. A solanesyl-diphosphate synthase localizes in glycosomes of Trypanosoma cruzi. J. Biol. Chem. 281:39339 -39348.
8. Fleisch H, Russell RGG, Straumann F. 1966. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 212: 901-903.
9. Fleisch H, Russell RGG, Francis MD. 1969. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1262-1264.
10. Francis MD, Russell RGG, Fleisch H. 1969. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165:1264 -1266.
11. Galel SA, Kirchhoff LV. 1996. Risk factors for Trypanosoma cruzi infection in California blood donors. Transfusion 36:227-231. (Pubitemid 26114464)
12. Hosfield DJ, et al. 2004. Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis. J. Biol. Chem. 279:8526-8529. (Pubitemid 38295905)
13. Kavanagh KL, et al. 2006. The molecular mechanism of nitrogencontaining bisphosphonates as antiosteoporosis drugs. Proc. Natl. Acad. Sci. U. S. A. 103:7829 -7834.
14. Kirchhoff LV. 1993. American trypanosomiasis (Chagas' disease) - a tropical disease now in the United States. N. Engl. J. Med. 329:639-644. (Pubitemid 23244817)
15. Lawrence RM, et al. 1996. Enantioselective synthesis of α-phosphono sulfonate squalene synthase inhibitors: chiral recognition in the interactions of an α-phosphono sulfonate inhibitor with squalene synthase. J. Am. Chem. Soc. 118:11668 -11669.
16. Liñares GE, Ravaschino EL, Rodriguez JB. 2006. Progresses in the field of drug design to combat tropical protozoan parasitic diseases. Curr. Med. Chem. 13:335-360.
17. Ling Y, et al. 2005. Bisphosphonate inhibitors of Toxoplasma gondii growth: in vitro, QSAR, and in vivo investigations. J. Med. Chem. 48:3130-3140. (Pubitemid 40628033)
18. Magnin DR, et al. 1995. 1,1-Bisphosphonate squalene synthase inhibitors: interplay between the isoprenoid subunit and the diphosphate surrogate. J. Med. Chem. 38:2596 -2605.
19. Magnin DR, et al. 1996. α-Phosphonosulfonic acids: potent and selective inhibitors of squalene synthase. J. Med. Chem. 39:657- 660.
20. Martin MB, et al. 2001. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. J. Med. Chem. 44:909 -916.
21. McTaggart F, et al. 1996. Inhibition of squalene synthase of rat liver by novel 3= substituted quimuclidines. Biochem. Pharmacol. 51:1477-1487.
22. Oldfield E. 2010. Targeting isoprenoid biosynthesis for drug discovery: bench to bedside. Acc. Chem. Res. 43:1216 -1226.
23. Poulter CD. 1990. Biosynthesis of non-head-to-tail terpenes. Formation of 1′-1 and 1′-3 linkages. Acc. Chem. Res. 23:70 -77.
24. Reszka AA, Rodan GA. 2004. Nitrogen-containing bisphosphonate mechanism of action. Mini-Rev. Med. Chem. 4:711-719. (Pubitemid 39149473)
25. Reszka AA, Rodan GA. 2003. Mechanism of action of bisphosphonates. Curr. Osteoporos. Rep. 1:45-52.
26. Rogers MJ, et al. 1999. Molecular mechanisms of action of bisphosphonates. Bone 24(5 Suppl):73S-79S. (Pubitemid 29202003)
27. Roelofs AJ, Thompson K, Ebetino FH, Rogers MJ, Coxon FP. 2010. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr. Pharm. Des. 16:2950-2960.
28. Rondeau J-M, et al. 2006. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem 1:267-273. (Pubitemid 43700307)
29. Rosso VS, et al. 2011. Synthesis and biological evaluation of New 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase. Bioorg. Med. Chem. 19:2211-2217.
30. Russell RGG, Rogers MJ. 1999. Bisphosphonates: from the laboratory to the clinic and back again. Bone 25:97-106. (Pubitemid 29322070)
31. Sealey-Cardona M, et al. 2007. Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives. Antimicrob. Agents Chemother. 51:2123-2129. (Pubitemid 46903104)
32. Szajnman SH, et al. 2012. Design, synthesis and biological evaluation of 1-(fluoroalkylidene)-1,1-bisphosphonic acids against Toxoplasma gondii targeting farnesyl diphosphate synthase. Org. Biomol. Chem. 10:1424-1433.
33. Szajnman SH, et al. 2008. Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase. Bioorg. Med. Chem. 16:3283-3290. (Pubitemid 351444820)
34. Szajnman SH, Ravaschino EL, Docampo R, Rodriguez JB. 2005. Synthesis and biological evaluation of 1-amino-1,1-bisphosphonates derived from fatty acids against Trypanosoma cruzi targeting farnesyl pyrophosphate synthase. Bioorg. Med. Chem. Lett. 15:4685- 4690.
35. Szajnman SH, Montalvetti A, Wang Y, Docampo R, Rodriguez JB. 2003. Bisphosphonates derived from fatty acids are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. Bioorg. Med. Chem. Lett. 13:3231-3235. (Pubitemid 37093834)
36. Szajnman SH, Bailey BN, Docampo R, Rodriguez JB. 2001. Bisphosphonates derived from fatty acids are potent growth inhibitors of Trypanosoma cruzi. Bioorg. Med. Chem. Lett. 11:789 -792.
37. Urbina JA. 2010. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop. 115:55- 68.
38. Urbina JA. 2010. New insights in Chagas' disease treatment. Drugs Fut. 35:409-420.
39. Urbina JA, et al. 1999. Trypanosoma cruzi contains major pyrophosphate stores, and its growth in vitro and in vivo is blocked by pyrophosphate analogs. J. Biol. Chem. 274:33609 -33615.
40. Urbina JA, Docampo R. 2003. Specific chemotherapy of Chagas' disease: controversies and advances. Trends Parasitol. 19:495-501. (Pubitemid 37329658)
41. Yardley V, et al. 2002. In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob. Agents Chemother. 46:929 -931.